

Daily evidence digest

20 May 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Phase 3 trial of Comirnaty (Pfizer) third dose, unexplained post-acute infection syndromes, first COVID-19 Breathalyzer

Peer reviewed journals featured:

- A phase 3 trial of a third dose of Comirnaty (Pfizer) vaccine in people aged 16+ years [here](#)
- A narrative review on unexplained post-acute infection syndromes [here](#)
- Observational studies on:
 - Co-infection with Omicron and Delta variants revealed by genomic surveillance [here](#)
 - Cross-variant immunity from Omicron without vaccination [here](#)
 - Comirnaty (Pfizer) protection against Omicron in children and adolescents [here](#)
 - Association of congenital and acquired cardiovascular conditions with COVID-19 severity among paediatric patients in the US [here](#)
- A machine learning model to identify long COVID [here](#)
- Commentary on:
 - Protecting NHS healthcare workers in future pandemics [here](#)
 - COVID-19 narratives and layered temporality [here](#)

Letters and correspondence discussed:

- Routine surveillance and vaccination on a US university campus during the spread of Omicron [here](#)

Pre-peer review articles featured:

- Differential evasion of Delta and Omicron immunity and enhanced fusogenicity of Omicron BA.4/5 and BA.2.12.1 subvariants [here](#)
- Lessons learned from a comparative policy analysis between Italian regions to cope with next COVID-19 pandemic impact [here](#)

News and blogs

- First Breathalyzer test to diagnose COVID-19 [here](#)
- The COVID-19 pandemic's true health cost [here](#)
- SARS-CoV-2 RNA can persist in stool months after respiratory tract clears virus [here](#)